Скачать или смотреть Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression

Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression

Speaker: Swaminathan IyerInstitution: The University of Texas MD Anderson Cancer CenterEvent: EHA 2023Format: InterviewSubject: LymphomaSubject: Rare DiseasesSubject: Peripheral T-Cell LymphomaField: TreatmentField: Trial UpdatesField: Immuno-OncologyField: Disease BiologyMedicines: Brentuximab VedotinMedicines: AntibodiesMedicines: CHPTrial: SGN35-032NCT04569032EudraCT 2020-002336-74Trial: ECHELON-2

Скачать Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

Информация по загрузке:

Cкачать музыку Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео Phase II study of brentuximab vedotin + CHP in patients with PTCL with less than 10% CD30 expression

Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and results of SGN35-032 (NCT04569032), a Phase II study of brentuximab combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) in patients with non-anaplastic large cell lymphoma (ALCL) peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression. Initial findings indicate that this combination is effective for patients with PTCL regardless of CD30 expression. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке